Companies › Inventprise
3 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IVT PCV-25 (Formulation B) 25-valent pneumococcal conjugate vaccine | – | Phase 2 | Pneumococcal Disease, Invasive | Dec 2026 |
| IVT GBS-06 Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, I | – | Phase 1 | Group B Streptococcal Infections | – |
| IVT Shigella-04 Live attenuated Shigella vaccine targeting 4 serotypes | – | Phase 1 | Shigella | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06611371 | IVT GBS-06 | Phase 1 | Group B Streptococcal Infections | Infectious disease | Aug 2025 |
| NCT07205926 | IVT Shigella-04 | Phase 1 | Shigella | Infectious disease | Jan 2026 |
| NCT06790290 | IVT PCV-25 (Formulation B) | Phase 2 | Pneumococcal Disease, Invasive | Infectious disease | Dec 2026 |
| NCT06790290 | IVT PCV-25 (Formulation B) | Phase 2 | Pneumococcal Disease, Invasive | Infectious disease | Dec 2026 |
| NCT06790290 | IVT PCV-25 (Formulation B) | Phase 2 | Pneumococcal Disease, Invasive | Infectious disease | Dec 2026 |
No annotated target.
–
LimmaTech Biologics SK Bioscience Green Cross Immorna Biotherapeutics Osivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.